Newsroom
August 9, 2024
A. Campbell Sullivan, PsyD, ABPP-CN, clinical associate professor, Glenn Biggs Institute for Alzheimer’s & Neurodegenerative Diseases, was quoted in this article. Read More
August 9, 2024
A. Campbell Sullivan, PsyD, ABPP-CN, clinical associate professor, Glenn Biggs Institute for Alzheimer’s & Neurodegenerative Diseases, was quoted in this article. Read More
August 9, 2024
A. Campbell Sullivan, PsyD, ABPP-CN, clinical associate professor, Glenn Biggs Institute for Alzheimer’s & Neurodegenerative Diseases, was quoted in this article. Read More
August 8, 2024
A. Campbell Sullivan, PsyD, ABPP-CN, clinical associate professor, Glenn Biggs Institute for Alzheimer’s & Neurodegenerative Diseases, was quoted in this article. Read More
July 31, 2024
Scientists from The University of Texas Health Science Center at San Antonio, also known as UT Health San Antonio, led a pilot study of the Food and Drug Administration-approved antiretroviral drug lamivudine, to determine if it could be a potential treatment for Alzheimer’s disease. Almost half of what makes up the human genome are […]
July 15, 2024
Sudha Seshadri, MD, Department of Neurology, director of the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, was interviewed for this article. Read More